Table 3

Clinical characteristics for elite athletes and non-athletes

Elite athletesNon-athletesp Value*p Value†
Asthma (n = 19)Non-asthma (n = 35)Asthma (n = 22)Non-asthma (n = 35)
eNO, ppb25.2 (3.84)21.3 (2.47)43.4 (7.85)14.7 (1.34)NS (0.056)<0.05
Atopy, n (%)11 (57.9)18 (51.4)22 (100)10 (28.6)<0.010.051
Mannitol test, n (%)‡4 (21.1)1 (2.9)18 (81.8)2 (5.7)<0.001NS
RDR0.018 (0.004)0.007 (0.001)0.083 (0.018)0.011 (0.004)<0.01NS
B eosinophils, 109/litre0.17 (0.02)0.12 (0.01)0.29 (0.04)0.12 (0.02)<0.02NS
ACQ3.7 (1.0)0.5 (0.2)7.4 (1.3)0.2 (0.2)<0.05NS
Symptoms, n (%)§18 (94.7)24 (68.6)21 (95.5)9 (25.7)NS<0.001
Current asthma, n (%)11 (57.9)1 (2.9)18 (81.8)0 (0)NSNS
Treatment, n (%)¶15 (78.9)0 (0)21 (95.5)0 (0)NSNS
  • Asthma = subjects with doctor-diagnosed asthma before entering the study. One athlete with “non-asthma” had a positive mannitol challenge test and asthma-like symptoms and was classified as having current asthma.

  • *Between elite and non-elite patients with asthma; †between elite and non-elite patients without asthma; ‡a positive mannitol challenge test; §all asthma-like symptoms (rest+exercise); ¶use of any asthma medication.

  • ACQ, asthma control questionnaire (mean score); eNO, exhaled nitric oxide (parts per billion); RDR, response dose ratio.